Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ALK |
Variant | D1225N |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ALK D1225N lies within the protein kinase domain of the Alk protein (UniProt.org). D1225N has been identified in the scientific literature (PMID: 37529699), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Apr 2024). |
Associated Drug Resistance | |
Category Variants Paths |
ALK mutant ALK D1225N |
Transcript | NM_004304.5 |
gDNA | chr2:g.29214054C>T |
cDNA | c.3673G>A |
Protein | p.D1225N |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004304.5 | chr2:g.29214054C>T | c.3673G>A | p.D1225N | RefSeq | GRCh38/hg38 |
NM_004304.4 | chr2:g.29214054C>T | c.3673G>A | p.D1225N | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK D1225N | lung adenocarcinoma | predicted - sensitive | Crizotinib | Case Reports/Case Series | Actionable | In a clinical case study, Xalkori (crizotinib) treatment resulted in a partial response in a patient with metastatic lung adenocarcinoma harboring ALK D1225N (PMID: 37529699). | 37529699 |
ALK D1225N | lung adenocarcinoma | predicted - sensitive | Ensartinib | Case Reports/Case Series | Actionable | In a clinical case study, Ensartinib (X-396) treatment resulted in a partial response in a patient with metastatic lung adenocarcinoma harboring ALK D1225N (PMID: 37529699). | 37529699 |